Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and ‐resistant Staphylococcus aureus : results from the CORE Registry

References

• Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44 Suppl A:19–23
   Google Scholar
• Food and Drug Administration. Guidance for industry: uncomplicated and complicated skin and skin structure infections – developing antimicrobial drugs for treatment. Available from www.fda.gov/cder/guidance/2566dft.pdf [Accessed on October 21, 2005]
   Google Scholar
• Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45: 287–93
   Google Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–85
   PubMed Web of Science ®Google Scholar
• Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005;41 Suppl 4:S269–72
   PubMed Web of Science ®Google Scholar
• Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005;11:928–30
   PubMed Web of Science ®Google Scholar
• Stevenson KB, Searle K, Stoddard GJ, Samore M. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in rural communities, western United States. Emerg Infect Dis 2005;11:895–903
   PubMed Web of Science ®Google Scholar
• Smith TL, Pearson ML, Wilcox KR, Cruz C, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493–501
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin—United States, 2002. MMWR 2002;51:565–7
   PubMedGoogle Scholar
• Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis 2005;18:300–5
   PubMed Web of Science ®Google Scholar
• Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004;38:994–1000
   PubMed Web of Science ®Google Scholar
• Fenton C, Keating GM, Curran MP. Daptomycin. Drugs 2004;64:445–55
   PubMed Web of Science ®Google Scholar
• Wise R, Andrews JM, Ashby JP. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001;48:563–7
   Google Scholar
• Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062–6
   PubMed Web of Science ®Google Scholar
• Cha R, Grucz RG, Jr., Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Anti-microb Agents Chemother 2003;47:1598–603
   Google Scholar
• Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539–46
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, Campanaro E, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38: 1673–81
   PubMed Web of Science ®Google Scholar
• Cubist Pharmaceuticals. Cubicin (daptomycin for injection) prescribing information. Lexington, MA; 2006 May 25. Report No.: 1108090803
   Google Scholar
• Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592–8
   PubMed Web of Science ®Google Scholar
• Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229–35
   PubMed Web of Science ®Google Scholar
• Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004;38:1377–82
   Google Scholar
• Cosgrove SE, Qi Y, Kaye KS, Harbarth S, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166–74
   PubMed Web of Science ®Google Scholar
• Reed SD, Friedman JY, Engemann JJ, Griffiths RI, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005;26: 175–83
   PubMed Web of Science ®Google Scholar
• Fowler VG, Jr., Boucher HW, Corey R, Abrutyn E, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653–65
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355: 666–74
   Google Scholar